T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
XYZ
Block Inc
XYZ
|
+$2.39B |
| 2 |
Carvana
CVNA
|
+$1.82B |
| 3 |
Microsoft
MSFT
|
+$1.5B |
| 4 |
Walt Disney
DIS
|
+$1.25B |
| 5 |
Spotify
SPOT
|
+$1.05B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$2.65B |
| 2 |
Intuit
INTU
|
+$2.08B |
| 3 |
Match Group
MTCH
|
+$1.87B |
| 4 |
Salesforce
CRM
|
+$1.76B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.61B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.08% |
| 2 | Healthcare | 16.24% |
| 3 | Consumer Discretionary | 15.33% |
| 4 | Communication Services | 13.82% |
| 5 | Financials | 12.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2651
Voyager Therapeutics
VYGR
$200M
| $235K | ﹤0.01% |
89,400
+25,900
| +41% | +$84.1K |
|
|
ASXC
2652
DELISTED
Asensus Surgical, Inc.
ASXC
| $235K | ﹤0.01% |
126,841
+24,600
| +24% | +$55.2K |
|
2653
Acacia Research
ACTG
$448M
| $234K | ﹤0.01% |
34,395
| – | – |
|
|
AGEN
2654
Agenus
AGEN
$310M
| $234K | ﹤0.01% |
2,272
-5
| -0.2% | -$565 |
|
2655
Grid Dynamics Holdings
GDYN
$635M
| $234K | ﹤0.01% |
+8,007
| New | +$196K |
|
2656
CEL-SCI Corp
CVM
$25.5M
| $233K | ﹤0.01% |
706
-350
| -33% | -$102K |
|
2657
Delek US
DK
$4.18B
| $232K | ﹤0.01% |
12,918
| – | – |
|
2658
Gorman-Rupp
GRC
$2.13B
| $232K | ﹤0.01% |
6,490
-102
| -2% | -$3.62K |
|
|
NOTV
2659
DELISTED
Inotiv
NOTV
| $232K | ﹤0.01% |
7,923
-100
| -1% | -$2.91K |
|
|
TRHC
2660
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $231K | ﹤0.01% |
8,825
| – | – |
|
2661
Quantum Corp
QMCO
$969M
| $230K | ﹤0.01% |
2,219
+344
| +18% | +$40.5K |
|
|
NAGE
2662
Niagen Bioscience
NAGE
$240M
| $230K | ﹤0.01% |
36,672
+11,281
| +44% | +$93K |
|
2663
Alpha Metallurgical Resources
AMR
$1.97B
| $229K | ﹤0.01% |
+4,600
| New | +$165K |
|
2664
Northrim BanCorp
NRIM
$603M
| $228K | ﹤0.01% |
21,452
-20,000
| -48% | -$206K |
|
2665
Universal Technical Institute
UTI
$1.46B
| $228K | ﹤0.01% |
33,800
-3,500
| -9% | -$22.8K |
|
|
CTO
2666
CTO Realty Growth
CTO
$824M
| $226K | ﹤0.01% |
12,624
-3,300
| -21% | -$60K |
|
2667
Pulse Biosciences
PLSE
$3.19B
| $226K | ﹤0.01% |
10,445
-2,000
| -16% | -$43K |
|
2668
First US Bancshares
FUSB
$90.7M
| $225K | ﹤0.01% |
20,950
| – | – |
|
|
VSTA
2669
DELISTED
Vasta Platform
VSTA
| $224K | ﹤0.01% |
49,057
-31,943
| -39% | -$201K |
|
|
MGI
2670
DELISTED
MoneyGram International, Inc. New
MGI
| $224K | ﹤0.01% |
27,942
-6,836
| -20% | -$65.1K |
|
2671
PAVmed
PAVM
$31.9M
| $223K | ﹤0.01% |
58
-1
| -2% | -$3.15K |
|
|
AGPU
2672
Axe Compute Inc
AGPU
$94.8M
| $223K | ﹤0.01% |
558
+204
| +58% | +$68.3K |
|
2673
Rocky Brands
RCKY
$356M
| $223K | ﹤0.01% |
+4,692
| New | +$233K |
|
2674
AnaptysBio
ANAB
$1.67B
| $221K | ﹤0.01% |
8,140
-126
| -2% | -$3.2K |
|
2675
Matinas BioPharma
MTNB
$1.49M
| $221K | ﹤0.01% |
3,396
| – | – |
|
Similar funds
T. Rowe Price Associates's Q3 2021 Portfolio in Review
As of Q3 2021, T. Rowe Price Associates held 3,048 positions worth $1.06T, down 1.6% from $1.08T the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q3 2021 filing shows 131 new, 1,029 increased, 1,524 reduced and 112 closed positions. Its largest new stake was Warby Parker: 17,643,113 shares worth $936M. The largest sale was Visa, an estimated $2.65B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q3 2021 buy was Warby Parker: 17,643,113 shares worth $936M.
- T. Rowe Price Associates added most to Block Inc in Q3 2021, an estimated $2.39B increase.
- T. Rowe Price Associates's biggest Q3 2021 reduction was Visa, cutting an estimated $2.65B.
- T. Rowe Price Associates fully exited Maxim Integrated Products in Q3 2021, selling an estimated $394M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $1.06T portfolio in Q3 2021.
- T. Rowe Price Associates opened 131 new positions and closed 112 in Q3 2021.
- T. Rowe Price Associates's portfolio value fell 1.6% quarter-over-quarter to $1.06T.
Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.